Chemo Drug Monitoring
The Problem
A significant percentage of cancer patients find out they are not eligible for their next round of chemotherapy when they arrive at the hospital, due to a low white blood cell count.
If the results of the hospital-administered test fall outside normal ranges, it leads to a delay in treatment and the patient being sent home. This is resource-inefficient, time consuming and burdensome for already vulnerable patients.
The Solution
Chemo Drug Monitoring
The Solution
miDiagnostics aims to address these challenges by providing patients with an easy-to-use test at home, requiring only a fingerprick of blood.
This alleviates the burden of travel and potential exposure to hospital infections.
Our Complete Blood Count (CBC) Reader in development is cost-effective and portable, making it suitable for home use. Testing can be self-administered, or completed by a caregiver, as it requires only a small volume of finger-prick blood, with results delivered straight to a mobile or computer. Results can be shared directly with a patient’s oncologist, empowering both the patient and clinician.
Respiratory Infections
The Problem
The inability to correctly and rapidly identify a respiratory tract infection can lead to outbreaks and ineffective treatments, resulting in an increase in suffering, time in hospital, spread of infection and antibiotic resistance.
Globally, there are millions of deaths each year related to respiratory tract infections, with COVID-19 as a prominent example. Lack of efficient and sufficient testing makes it difficult to curb outbreaks quickly.
As it stands, most testing either takes place in the laboratory, meaning delays in receiving results, or if portable testing is possible, requires expensive equipment, takes time and is inefficient. There is a growing call for tests which can analyze for multiple targets, including bacteria and viruses, simultaneously.
The Solution
Respiratory Infections
The Solution
miDiagnostics aims to offer affordable and decentralized testing to enable rapid and appropriate treatment selection.
Our Molecular Diagnostics (MolDx) Reader offers tests that can analyze multiple pathogens at the same time in a single test, enabling the screening of patients by their symptoms. The test can provide lab-quality results in a wide range of healthcare settings globally, making it ideal for tracking and reducing the spread respiratory tract infections.
Our CBC Reader enables the differentiation between viral and bacterial infections, allowing healthcare providers to make informed decisions on prescribed therapeutics, such as antibiotics.
AMR (Antimicrobial Resistance)
The Problem
By 2050 antimicrobial resistance is predicted to cause more annual deaths than cancer.
It is a well recognized major public health threat, with an estimated global economic impact of $35 billion annually. A major contributor to AMR is the over-prescription of antibiotics. In sexually-transmitted diseases, for example, antibiotics are often prescribed before test results have been processed and may therefore be entirely unnecessary.
The Solution
AMR (Antimicrobial Resistance)
The Solution
Using our MolDx Reader enables results identifying pathogens in under 15 minutes, empowering clinicians to make the most appropriate decision regarding treatment options.
Our CBC Reader supports the differentiation between viral and bacterial infections. Both readers reduce unnecessary prescriptions and preserve antibiotics as a last resort for those who need them.
“miDiagnostics has the potential to disrupt and transform the industry by making diagnostic information available to clinician and patient alike.”
“Its easy-to-use and cost-efficient test will revolutionize point-of-care testing by directly engaging with patients and enabling speedy intervention”
“When it comes to making diagnostic decisions, it’s time to stop focusing on firefighting, it’s time to start investing in smoke detectors”